These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31200829)

  • 21. Targeting the Hedgehog and Notch signaling pathways.
    Weiss GJ
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1820-1. PubMed ID: 22005544
    [No Abstract]   [Full Text] [Related]  

  • 22. Hedgehog drugs begin to show results.
    Garber K
    J Natl Cancer Inst; 2008 May; 100(10):692-7. PubMed ID: 18477794
    [No Abstract]   [Full Text] [Related]  

  • 23. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
    Arnhold V; Boos J; Lanvers-Kaminsky C
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hedgehog beyond medulloblastoma and basal cell carcinoma.
    Teglund S; Toftgård R
    Biochim Biophys Acta; 2010 Apr; 1805(2):181-208. PubMed ID: 20085802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hedgehog hopes lifted by approval... and stung by failure.
    Allison M
    Nat Biotechnol; 2012 Mar; 30(3):203. PubMed ID: 22398601
    [No Abstract]   [Full Text] [Related]  

  • 28. Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis.
    Lin Z; Li S; Sheng H; Cai M; Ma LY; Hu L; Xu S; Yu LS; Zhang N
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2469-2478. PubMed ID: 27601167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
    Yin VT; Esmaeli B
    Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
    Kean S
    Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
    [No Abstract]   [Full Text] [Related]  

  • 32. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.
    Banerjee U; Hadden MK
    Expert Opin Drug Discov; 2014 Jul; 9(7):751-71. PubMed ID: 24850423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hedgehog signaling inhibitors in solid and hematological cancers.
    Cortes JE; Gutzmer R; Kieran MW; Solomon JA
    Cancer Treat Rev; 2019 Jun; 76():41-50. PubMed ID: 31125907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
    Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
    Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hedgehog pathway inhibitors: a patent review (2009--present).
    Hadden MK
    Expert Opin Ther Pat; 2013 Mar; 23(3):345-61. PubMed ID: 23294277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.